Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 23;8(8):1959-1963.
doi: 10.1182/bloodadvances.2023011168.

Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy

Maria Gabelli  1   2 , Macarena Oporto-Espuelas  3 , Saskia Burridge  1 , Jan Chu  1 , Susan Farish  1 , Emma Hedges  4 , Kirsty Ware  4 , Lindsey Williams  1 , Lindsey Young  1 , Rajesh Alajangi  5 , Philip Ancliff  4 , Jack Bartram  4 , Denise Bonney  6 , Lenka Chenchara  7 , Robert Chiesa  1 , Chiara Cugno  7 , Katharine Hodby  5 , Katarzyna A Jalowiec  8 , Arina Lazareva  1 , Giovanna Lucchini  1 , Oana C Mirci-Danicar  9 , Khushnuma Mullanfiroze  1 , Vesna Pavasovic  4 , Anupama Rao  4 , Kanchan Rao  1 , Lynne Riley  4 , Sujith Samarasinghe  4 , Geoff Shenton  10 , Juliana Silva  1 , Ajay Vora  4 , Rachael Hough  8 , Persis J Amrolia  1   3 , Sara Ghorashian  4   11
Affiliations

Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy

Maria Gabelli et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: P.J.A. declares patents with and royalties from University College London Business and Autolus; received research funding from Autolus; and declares consultancy with Beam Therapeutics. S.G. received honoraria and speaker’s fees from Novartis and declares patents with and royalties from University College London Business. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Oucomes for children with early loss of B-cell aplasia following CAR T according to further therapy (maintenance vs stem cell transplantation). EFS (A) and OS (B) for patients treated with allogeneic SCT (red line) or maintenance therapy (blue line) for early LBCA after CAR T-cell treatment.
See this image and copyright information in PMC

References

    1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. - PMC - PubMed
    1. Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414–5424. - PMC - PubMed
    1. Laetsch TW, Maude SL, Rives S, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA Trial. J Clin Oncol. 2023;41(9):1664–1669. - PMC - PubMed
    1. Pillai V, Muralidharan K, Meng W, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3(22):3539–3549. - PMC - PubMed
    1. Pulsipher MA, Han X, Maude SL, et al. Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov. 2022;3(1):66–81. - PMC - PubMed

MeSH terms